Companies: 48,874 Total Market Cap: 132262354351170.73

Scilex Holding Company

NASDAQ: SCLX
Healthcare Drug Manufacturers - General
Rank #34710
Market Cap 22.04 M
Volume 98,421
Price 4.21
Change (%) 0.00%
Country or region United States United States

Scilex Holding Company's latest marketcap:

22.04 M

As of 05/17/2025, Scilex Holding Company's market capitalization has reached $22.04 M. According to our data, Scilex Holding Company is the 34710th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 22.04 M
Revenue (ttm) 50.71 M
Net Income (ttm) -74,510,000
Shares Out 5.24 M
EPS (ttm) -14.13
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/23/2025
Market Cap Chart
Data Updated: 05/17/2025

Scilex Holding Company's yearly market capitalization.

Scilex Holding Company has seen its market value drop from $173.19 M to $22.04 M since 2021, representing a total decrease of 87.27% and an annual compound decline rate (CAGR) of 45.70%.
Date Market Cap Change (%)
05/17/2025 $22.04 M -72.51%
12/31/2024 $76.36 M -61.74%
12/29/2023 $199.59 M -64.61%
12/30/2022 $563.98 M 225.64%
12/31/2021 $173.19 M

Company Profile

About Scilex Holding Company

Scilex Holding Company specializes in acquiring, developing, and commercializing non-opioid pain management products designed for acute and chronic pain relief.

Commercial Products

  • ZTlido (lidocaine topical system) 1.8%: A prescription lidocaine topical product for neuropathic pain associated with postherpetic neuralgia (PHN).
  • ELYXYB: A ready-to-use oral solution for acute migraine treatment in adults, with or without aura.
  • GLOPERBA: A liquid oral form of colchicine, used to prevent painful gout flares in adults.

Product Pipeline

  • SP-102 (SEMDEXA): A novel viscous gel corticosteroid for epidural injections, completing Phase 3 trials for lumbosacral radicular pain (sciatica).
  • SP-103 (lidocaine topical system) 5.4%: An advanced formulation of ZTlido for chronic neck and low back pain (LBP), having completed Phase 2 trials.
  • SP-104 (low-dose naltrexone): A delayed-release naltrexone hydrochloride capsule, completing Phase 1 trials for fibromyalgia treatment.

Strategic Partnerships

Scilex has collaborations with:

  • Oishi and Itochu: For developing lidocaine tape products, including ZTlido and SP-103.
  • Lifecore Biomedical, LLC: For clinical trial material manufacturing and development services for SEMDEXA.

Headquarters: Palo Alto, California.

Frequently Asked Questions

As of 05/17/2025, Scilex Holding Company (including the parent company, if applicable) has an estimated market capitalization of $22.04 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Scilex Holding Company global market capitalization ranking is approximately 34710 as of 05/17/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region United States
Founded 2011
IPO Date n/a
Employees 115
CEO Jaisim Shah
Sector Healthcare
Industry Drug Manufacturers - General
Address 960 San Antonio Road
Palo Alto, California 94303
United States
Website https://www.scilexholding.com
People Also Watch
Eli Lilly
757.39 0.00%
JNJ
151.33 0.00%
AbbVie
184.02 0.00%
Novo Nordisk
64.37 0.00%